Immunitybio Inc Revenue Growth Rates (IBRX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Immunitybio inc   (NASDAQ: IBRX)
 

IBRX's Revenue Growth by Quarter and Year

Immunitybio Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IBRX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 51.24
1st Quarter March 44.21
FY 95.45

IBRXs Annual Revenue
Immunitybio Inc 's Revenue in the fiscal year 2025 $ 113.29 millions
Immunitybio Inc 's Revenue in the fiscal year 2024 $ 14.75 millions
Immunitybio Inc 's Revenue in the fiscal year 2023 $ 0.62 millions
Immunitybio Inc 's Revenue in the fiscal year 2022 $ 0.24 millions
Immunitybio Inc 's Revenue in the fiscal year 2021 $ 0.93 millions




IBRX Revenue second quarter 2026 Y/Y Growth Comment
Immunitybio inc reported Revenue surge of 93.87% year on year in the second quarter 2026, to $ 51.24 millions, this is lower than Immunitybio Inc 's recent average Revenue surge of 690.64%.

Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 7 other companies have achieved higher Revenue growth. While Immunitybio Inc ' s Revenue jump of 93.87% ranks overall at the positon no. 130 in the second quarter 2026.


IBRX Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 407.15 % 5292.86 % 100 %
3rd Quarter September - 424.71 % 7537.5 % -33.33 %
2nd Quarter June 93.87 % 2417.14 % 2525 % 0 %
1st Quarter March 167.62 % 41200 % -88.89 % 3500 %
FY   - 668.14 % 2279.03 % -

Financial Statements
Immunitybio Inc 's second quarter 2026 Revenue $ 51.24 millions IBRX's Income Statement
Immunitybio Inc 's second quarter 2025 Revenue $ 26.43 millions Quarterly IBRX's Income Statement


IBRX Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 19.43 % 23.57 % 75 %
3rd Quarter September - 21.3 % 481.9 % 100 %
2nd Quarter June 15.9 % 59.99 % 2525 % -88.89 %
1st Quarter March 15.46 % 118.81 % -71.43 % 414.29 %
FY (Year on Year)   - 668.14 % 2279.03 % -


Back to IBRX Growth rate Comparisons >> Back to IBRX Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #8
Healthcare Sector #44
Overall #130

Revenue Y/Y Growth Statistics
High Average Low
10238.41 % 690.64 % -74.3 %
(Mar 31 2025)   (Dec 31 2022)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #8
Healthcare Sector #44
Overall #130
Revenue Y/Y Growth Statistics
High Average Low
10238.41 % 690.64 % -74.3 %
(Mar 31 2025)   (Dec 31 2022)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Immunitybio Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
6700 % 251.94 % -96.41 %
(Sep 30 2020)  


IBRX's II. Quarter Q/Q Revenue Comment
Immunitybio inc achieved in the II. Quarter 2026 below company average Revenue jump of 15.9% quarter on quarter, to $ 51.24 millions.

Within Biotechnology & Pharmaceuticals industry 15 other companies have achieved higher Revenue quarter on quarter growth. While Immunitybio Inc 's Revenue growth quarter on quarter, overall rank is 595.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #16
Healthcare Sector #111
Overall #595
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #16
Healthcare Sector #111
Overall #595
Revenue Q/Q Growth Statistics
High Average Low
6700 % 251.94 % -96.41 %
(Sep 30 2020)  


IBRX's II. Quarter Q/Q Revenue Comment
Immunitybio inc achieved in the II. Quarter 2026 below company average Revenue jump of 15.9% quarter on quarter, to $ 51.24 millions.

Within Biotechnology & Pharmaceuticals industry 15 other companies have achieved higher Revenue quarter on quarter growth. While Immunitybio Inc 's Revenue growth quarter on quarter, overall rank is 595.


Immunitybio Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 165.79 $ 140.98 $ 113.29 $ 82.56 $ 56.60
Y / Y Revenue Growth (TTM) 192.92 % 351.53 % 668.31 % 1025.95 % 4227.22 %
Year on Year Revenue Growth Overall Ranking # 9 # 6 # 5 # 8 # 75
Seqeuential Revenue Change (TTM) 17.6 % 24.44 % 37.23 % 45.86 % 81.28 %
Seq. Revenue Growth (TTM) Overall Ranking # 197 # 48 # 56 # 32 # 35


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Immunitybio Inc 's cumulative twelve months Revenue were $ 166 millions, company would post below average annual Revenue growth of 81.28% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Immunitybio Inc 's Revenue growth from the 44.21% growth in Mar 31 2026.

Among companies within the Healthcare sector 4 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 6 to 9.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 9
Healthcare Sector # 5
Overall # 9

Revenue TTM Y/Y Growth Statistics
High Average Low
10238.41 %
 539.93 %
-90.27 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 9
Sector # 55
S&P 500 # 197
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Immunitybio Inc 's cumulative twelve months Revenue were $ 166 millions, company would post below average annual Revenue growth of -90.27% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Immunitybio Inc 's Revenue growth from the 44.21% growth in Mar 31 2026.

Among companies within the Healthcare sector 4 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 6 to 9.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 9
Healthcare Sector # 5
Overall # 9

Revenue TTM Y/Y Growth Statistics
High Average Low
10238.41 %
539.93 %
-90.27 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 9
Sector # 55
S&P 500 # 197




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
IBRX's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________162.99%$ 162.992 millions
Cormedix Inc 156.52%$ 156.515 millions
Ataibeckley Inc 137.00%$ 136.996 millions
Pavmed Inc 135.71%$ 135.714 millions
Xilio Therapeutics Inc 131.22%$ 131.222 millions
Tenon Medical Inc 126.77%$ 126.773 millions
Sonida Senior Living Inc 122.02%$ 122.024 millions
Bridgebio Pharma Inc 120.39%$ 120.392 millions
Autolus Therapeutics Plc118.37%$ 118.367 millions
Neuraxis Inc 115.72%$ 115.717 millions
Renovorx Inc 115.40%$ 115.403 millions
Ars Pharmaceuticals Inc 114.15%$ 114.150 millions
Foghorn Therapeutics Inc 112.68%$ 112.677 millions
60 Degrees Pharmaceuticals Inc 106.04%$ 106.044 millions
Mobia Medical Inc 102.35%$ 102.352 millions
Ptc Therapeutics inc 101.55%$ 101.548 millions
Eton Pharmaceuticals Inc 98.63%$ 98.631 millions
Immunitybio inc 93.91%$ 93.907 millions
Syndax Pharmaceuticals Inc 91.76%$ 91.759 millions
Phathom Pharmaceuticals Inc 88.02%$ 88.021 millions
Fennec Pharmaceuticals Inc 85.18%$ 85.184 millions
Alamar Biosciences Inc 82.08%$ 82.075 millions
Seastar Medical Holding Corp81.95%$ 81.953 millions
Sera Prognostics Inc 76.47%$ 76.471 millions
Innovative Eyewear Inc 74.46%$ 74.459 millions
Madrigal Pharmaceuticals Inc 71.17%$ 71.169 millions
Tg Therapeutics Inc 70.27%$ 70.272 millions
Tarsus Pharmaceuticals Inc 69.41%$ 69.406 millions
Hyperfine Inc 67.70%$ 67.698 millions
Alnylam Pharmaceuticals Inc 66.86%$ 66.856 millions


About Immunitybio Inc Revenue Growth Rates (IBRX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Immunitybio Inc (CIK 1326110).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001326110-26-000079
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Immunitybio Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.